Clinical trials: Small Cell Carcinoma of Lung
Small Cell Lung Carcinoma
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
This is the first study where BAY1000394 is given in combination with chemotherapy: cisplatin / etoposide or carboplatin / etoposide. Patients with small cell lung cancer will be treated.
- Trial name
- NCT01573338
- Testing
- Roniciclib (BAY1000394), Etoposide, Cisplatin
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 43 people
- Sponsor
- Bayer
Radiotherapy, Non Small Cell Lung Cancer
Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC
The hypothesis for this study is that addition of a moderate dose of radiotherapy to the primary tumor and mediastinal nodes after three months of medical treatment could reduce the tumor burden, partly as an abscopal effect, and…
- Conditions
- Radiotherapy, Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Quality of Life
- Trial name
- MARS (NCT04530708)
- Testing
- Thoracic radiotherapy
- Where
- 3 sites in Sweden
- Volunteers
- 162 people
- Sponsor
- Swedish Lung Cancer Study Group
Non-small Cell Lung Cancer
Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer
This study aims to enroll non-small cell lung cancer patients who have undergone at least two rounds of standard treatment for drug resistance/recurrence.
- Trial name
- NCT06406608
- Testing
- Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Locally Advanced Non-Small Cell Lung Cancer, Metastatic NSCLC
Patient's Whole Process Follow-up Management(HOPE-1)
Our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.
- Trial name
- HOPE-1 (NCT05339568)
- Testing
- Patients' whole process follow-up and management platform
- Where
- China
- Volunteers
- 1,268 people
- Sponsor
- Qianfoshan Hospital
Non-Small Cell Lung Cancer
The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients
This study is designed to evaluate the predicted potential of quantitative T cell repertoire (TCR) of T cell receptor chains using next-generation sequencing (NGS) in the treatment of the anti-programmed death-ligand 1 (PD-L1)…
- Trial name
- NCT03228368
- Testing
- Atezolizumab (MPDL3280A)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Carcinoma, Non-Small-Cell Lung
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
This study determines tumor response rate, time to tumor progression and survival rate at 1 year produced by OSI-774 in previously treated African American patients with nonsmall cell lung cancer.
- Trial name
- NCT00230126
- Testing
- erlotinib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Recurrent Non Small Cell Lung Cancer
APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer
This study will compare the anti-tumor efficacy of apricoxib and erlotinib with placebo and erlotinib as measured by time to disease progression to test the hypothesis that down regulation of COX-2 and EGFR pathways in patients…
- Trial name
- TP2001-201 (NCT00652340)
- Testing
- apricoxib/erlotinib
- Where
- 47 sites in United States
- Volunteers
- 120 people
- Sponsor
- Tragara Pharmaceuticals, Inc.
Non-Small Cell Carcinoma of Lung, Immunotherapy
Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy
This study is a retrospective, multicenter, observational cohort study in patients with advanced or locally advanced non-small cell lung cancer (NSCLC).
- Conditions
- Non-Small Cell Carcinoma of Lung, Immunotherapy, Advanced Non-Small Cell Lung Cancer
- Trial name
- NCT07668037
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Double Blind
SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
This is a multicenter Phase II/III study evaluating the efficacy and safety of SCTB41 combined with chemotherapy versus tislelizumab combined with chemotherapy as first-line treatment in patients with driver-negative locally…
- Trial name
- NCT07662395
- Testing
- SCTB41, Tislelizumab, Paclitaxel
- Where
- China
- Volunteers
- 410 people
- Sponsor
- Sinocelltech Ltd.
Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen
This phase II trial tests the safety and side effects of durvalumab and grid therapy in treating patients with non-small cell lung cancer who have progressed during or within 6 months of durvalumab administration for non-small…
- Trial name
- NCT05443971
- Testing
- Durvalumab, Radiation Therapy, Biospecimen Collection
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Non-small Cell Lung Cancer, Breast Cancer
Copenhagen Master Observational Trial
The primary objectives of this prospective non-interventional study (NIS) are to assess and describe outcomes in relation to biomarkers, including whole-genome sequencing (WGS) in patients with non- small cell lung cancer (NSCLC)…
- Trial name
- C-MOT (NCT05145244)
- Testing
- No Intervention: Observational Cohort
- Where
- Denmark
- Volunteers
- 2,400 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
NSCLC (Non-small Cell Lung Cancer)R
A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation
This interventional study will evaluate the effectiveness, safety, and tolerability of pembrolizumab in combination with lenvatinib in adults with metastatic non-small cell lung cancer (NSCLC) who have a confirmed RET gene…
- Trial name
- LPR-2 (NCT07809256)
- Testing
- lenvatinib pembrolizumab
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- EuroCityClinic LLC
Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally…
- Conditions
- Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C
- Trial name
- NCT06343402
- Testing
- BBO-8520, Pembrolizumab, BBO-10203
- Where
- 38 sites in United States, Australia and 3 more
- Volunteers
- 350 people
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Small Cell Lung Cancer, Radiotherapy
Abscopal Effect for Metastatic Small Cell Lung Cancer
Patients with small cell lung cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1.
- Conditions
- Small Cell Lung Cancer, Radiotherapy, Thymalfasin
- Trial name
- NCT02542137
- Testing
- Radiotherapy, Thymalfasin
- Sponsor
- Zhejiang Provincial People's Hospital
Non-Small Cell Lung Cancer (NSCLC)
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients
- Trial name
- NCT01951157
- Testing
- Docetaxel, Gemcitabine, Lurbinectedin (PM01183)
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- PharmaMar
Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation
Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States
This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation who received treatment with capmatinib…
- Trial name
- NCT06161051
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Comprehensive Geriatric Assessment and Complications Following Lung Resection for Lung Cancer
schema : Prospective prognostic study The main objective is to study the value of the Comprehensive Geriatric Assessment in predicting the risk of post operative complications after lung resection for cancer.
- Trial name
- OPERAGE (NCT01956331)
- Where
- 25 sites in France
- Volunteers
- 302 people
- Sponsor
- Groupe Francais De Pneumo-Cancerologie
Non Small Cell Lung Cancer (NSCLC)
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
To assess the impact of prophylactic treatment on the incidence of adverse events in advanced NSCLC patients (post chemotherapy) treated with dacomitinib daily as a single agent.
- Trial name
- ARCHER 1042 (NCT01465802)
- Testing
- Dacomitinib, Doxycycline, Probiotic
- Where
- 81 sites in United States, South Korea
- Volunteers
- 236 people
- Sponsor
- Pfizer
Small Cell Lung Cancer (SCLC)
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
The purpose of this trial is to compare the effects of TAS-102 with either amrubicin or topotecan (drugs used in Small Cell Lung Cancer) on lung cancer to find out the effects on survival, how much time may pass without disease…
- Trial name
- NCT01904253
- Testing
- TAS-102, Amrubicin (Japan), Topotecan (Japan/Europe)
- Where
- 23 sites in Germany, Italy and 1 more
- Volunteers
- 18 people
- Sponsor
- Taiho Oncology, Inc.
Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II
Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) with concurrent chemotherapy in the management of stage II and III non-small cell lung cancer (NSCLC).
- Conditions
- Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- NCT05873439
- Testing
- Genomically Guided Radiation Therapy (RT)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.